At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Alisertib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
In Brief
A Phase 2 clinical trial evaluating Alisertib and Laboratory Biomarker Analysis for Myxofibrosarcoma and 7 related conditions. Completed, enrolled 72 participants across 235 sites.
Detailed Summary
This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartAug 2012
Primary CompletionAug 2015
TodayJul 2026
First PostedJul 30, 2012
Enrollment StartAug 22, 2012
Primary CompletionAug 2, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.9 years ago
Interventions
Alisertibdrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies